RasGRP1 is a Ras guanine nucleotide exchange factor, and an essential regulator of lymphocyte receptor signaling. In mice, Rasgrp1 deletion results in defective T lymphocyte development.
Introduction
RasGRP1, a Ras guanine nucleotide exchange factor (RasGEF), is a key protein regulating effector kinases upon T cell receptor (TCR) signaling [1] . RasGRP1 expression levels regulate the output of lymphocyte receptor signaling in a dose-dependent manner [2, 3] . Complete lack of Rasgrp1 in mice results in a defect in positive selection of thymocytes (developing T cells), and immune deficiency, both in wildtype mice and mice expressing a transgenic TCR [4, 5] . Recent studies described RASGRP1 loss in patients with immune deficiencies [6, 7] , and RasGRP1 loss-of-function in autoimmune lymphoproliferative syndrome (ALPS) [8] .
Dysregulation of RasGRP1 expression levels has been suggested to play a role as well in leukemia and autoimmunity. Increased expression of Rasgrp1 has been detected in murine models and patients with T-ALL [9, 10] , and some studies demonstrated aberrant expression levels of RasGRP1 in patients with autoimmunity. For example, patients with systemic lupus erythematosus with splice variants of RasGRP1 expressed decreased RasGRP1 protein levels [11] , while in rheumatoid arthritis increased mRNA and a contrasting decrease in RasGRP1 protein was shown in total T cells [12] . Furthermore, single nucleotide polymorphisms (SNPs) in the RASGRP1 locus have been linked to autoimmunity [13] [14] [15] . For instance, SNPs in coding regions have been shown to affect lymphocyte receptor signaling in cell lines [2] , and in mice [16] . It has not been established if non-coding SNPs in RasGRP1 affect its expression levels. In sum, it is unknown how RasGRP1 expression is regulated in T cells and if RasGRP1 dosage alterations may impact T cell function and immunological health. We set out to mechanistically understand how RasGRP1 expression levels are regulated and investigate if aberrant expression of RasGRP1 may contribute to inflammatory disease.
Results
To test whether decreased Rasgrp1 expression levels can in principal cause autoimmunity, we assessed immune-phenotypes of WT (+/+) to Rasgrp1-heterozygous (+/-) and Rasgrp1-KO (-/-) mice.
All mice were on a C57BL/6 background, which is not prone to develop autoimmunity [17] .
Thymocytes of Rasgrp1 heterozygous mice express approximately half of normal Rasgrp1 protein levels ( Fig 1A) . Analysis of stages of thymocyte development ( Fig 1B) by flow cytometry showed that aberrant Rasgrp1 expression impaired positive thymocyte selection. As reported previously [18] , we observed that Rasgrp1 -/mice displayed an accumulation of CD44 -CD25 + double negative (DN3) thymocytes, indicating defective b-selection. By contrast, Rasgrp1 +/mice did not show accumulation of this early T cell progenitor population directly prior to b-selection ( Fig 1C, Fig 1-Suppl A) . The positive selection process shapes the T cell receptor (TCR) repertoire as assembled, mature TCRs are functionally tested in this selection process [19] and alterations in the repertoire can lead to selfrecognition in the periphery and autoimmune diseases. We observed that intact Rasgrp1 expression is critical for positive selection; the numbers of TCRb + CD69 + double positive (DP) thymocytes and CD4 + SP cells were decreased in Rasgrp1 +/mice ( Fig 1D,E, Fig 1- Suppl B-C). As expected and reported [18] , without any Rasgrp1 expression (in Rasgrp1 -/mice) these two populations were nearly absent ( Fig 1D,E, Fig 1- Suppl B-C). These results showed an inverse effect of RasGRP1 expression on thymic positive selection; half the RasGRP1 protein dosage already resulted in less efficient positive selection.
Next, we analyzed serum for the presence of anti-nuclear antibodies, a commonly used indicator for autoimmune features (ANA, Fig 1-suppl D) . In 11 weeks old mice, we observed that absence of Rasgrp1 led to ANA production, while Rasgrp1 +/and WT mice produced no ANA at all ( Fig 1F) .
These results agreed with earlier studies performed in Rasgrp1 -/mice [20, 21] . However, by age 24 weeks we also detected serum ANA in approximately half of the heterozygous Rasgrp1 +/mice, while only 1 out of 11 wildtype mice were ANA positive ( Fig 1G) . Thus, decreased expression of Rasgrp1 led to an increased risk of development of autoimmunity in C57BL/6 mice over time.
Based on these in vivo findings in C57BL/6 mice, we hypothesized that RasGRP1 expression could be dysregulated in human autoimmunity. Previous reports showed that peripheral blood total T cells (Both CD4 + and CD8 + ) from patients with Rheumatoid Arthritis (RA) display higher RASGRP1 mRNA levels than healthy donors, and the expression levels of RASGRP1 inversely correlate with disease activity scores [12] . We set out to explore RASGRP1 expression in patients with oligoarticular Juvenile Idiopathic Arthritis (JIA), a relapsing/remitting form of autoimmunity in children. We analyzed RASGRP1 expression in peripheral blood CD4 + T cells from patients who were either in remission or showed active inflammation, and compared this to healthy controls. Furthermore, we analyzed CD4 + T cells from the site of active inflammation; synovial fluid (SF). We observed that RASGRP1 mRNA expression was significantly decreased in CD4 + T cells from patients with active autoimmune disease compared to healthy controls, and this was most pronounced in synovial fluid at the site of active inflammation (Figs 2A, 2-SupplA,B). These results imply that there is active maintenance of RASGRP1 expression levels in CD4 + T cells with instances of decreased expression of RASGRP1 mRNA levels specifically under autoimmune inflammatory conditions and motivated us to next investigate regulation of RasGRP1 mRNA expression.
To identify non-coding elements that could affect RASGRP1 gene expression in the context of autoimmunity, we analyzed the locations of candidate causal non-coding SNPs associated with autoimmunity. We found two distinct regions with clusters of candidate causal SNPs associated with Crohn's disease, Type 1 Diabetes, and RA. One region was positioned upstream of the RASGRP1 promoter, suggesting the presence of regulatory elements relevant to autoimmunity (Figs 2B, 2-Suppl B). Next, we analyzed Histone 3 lysine 27 acetylation (H3K27ac), indicating transcriptional enhancers.
Enhancers are essential to tune gene regulation, and contribute to cell identity and function in health and disease [22, 23] . In human CD4 + T cells, the H3K27ac signal on RasGRP1 elements was more pronounced in activated/stimulated T cells, and co-localized with the SNP clusters (Figs 2B) . Notably, we identified a prominent, single H3K27ac peak marking a putative enhancer (autoimmunity-associated enhancer 1). These data suggest that RASGRP1 expression in CD4 + T cells is regulated by enhancers and that SNPs in these elements could contribute to RASGRP1 dysregulation and autoimmunity.
To test whether the putative autoimmunity-associated enhancer 1 indeed regulates RASGRP1 expression, we perturbed this non-coding element with CRISPR-Cas9 editing in the Jurkat T cell lymphoma line [24] . First, we transfected cells with Cas9-Ribonucleoprotein (RNP) complexes targeting exon 2 to generate a RASGRP1-KO clone (RG1-KO) with loss of RasGRP1 protein ( Fig 3A, 
3-Suppl A, B
). An unedited clone (unedited-i) was used as control. Having established this platform, we targeted autoimmunity-associated enhancer 1 ( Next, we capitalized on a previously optimized platform to analyze RasGRP1 signaling through flow cytometry analyses of phosphorylated ERK a kinase in the canonical Ras-MAPK pathway [2] (Phospho-flow). Phospho-flow allows quantitative detection of defects in ERK signaling such as in JPRM441, a Jurkat line expressing low levels of endogenous RasGRP1 [25] . Phospho-flow analyses We aimed to mechanistically understand how this enhancer region is impacting RasGRP1 expression and we postulated that factors binding to the RasGRP1 enhancer may be distinct in clones Enh-i and Enh-ii. To identify transcription factors regulating RASGRP1 expression by binding autoimmunityassociated enhancer 1, we performed AP-MS (affinity purification mass spectrometry) analysis [26] .
The scrambled sequence of the 42 base pairs (Fig 4 Suppl A) that were deleted in clone Enh-ii, resulted in a loss of binding of CBFB and RUNX1, which together form a transcriptional heterodimer, as well as loss of binding of several ZBTB family members ( Fig 4A) . We focused on RUNX1 because this factor has been identified as an important transcriptional regulator in hematopoiesis [27] and T cell development [28] , during T cell responses [29] , and mutations in RUNX1 have been described to play a role in T-ALL [30] . Furthermore, variants in RUNX1 have been associated with autoimmunity [31, 32] , and RUNX1 binding sites have been associated with super-enhancers in JIA [33] .
To demonstrate the relevance of RUNX1 in CD4 + T cells in autoimmunity, we analyzed RUNX1 expression levels in patients with JIA. We show a decreased RUNX1 expression in patients with active disease, which again was most pronounced in the synovial fluid, similar to RASGRP1 . These data provide a novel link between RUNX1 and RasGRP1, and a mechanistic explanation for the reduced RasGRP1 expression in clone Enh-ii, because RUNX1 can no longer bind to the regulatory enhancer element that is key for RASGRP1 transcription.
Discussion
We show for the first time that decreased expression levels of Rasgrp1 induce autoimmunity in mice through a reduction of positive thymocyte selection, and that decreased RASGRP1 in CD4 + T cells is specifically detected under circumstances of active autoimmunity in patients. In mice, reduced expression of RASGRP1 mildly disturbs T cell development, and results in a delayed onset of disease compared to complete deletion of RASGRP1. We detected reduced levels of RASGRP1 in peripheral CD4 + T cells in patients, specifically in the synovial fluid at the site of active inflammation, suggesting that dysregulation of RASGRP1 expression occurs in activated T cells. In line with this, we identified a RASGRP1 enhancer containing a cluster of autoimmunity-risk SNPs, that showed a higher H3K27ac signal in previously activated CD4 + memory T cells.
Mechanistically, we show that transcription factor RUNX1 is essential for regulation of RASGRP1 expression levels. RUNX1 has been identified as an important transcription factor in hematopoiesis and T cell development, and mutations in RUNX1 have been described to play a role in T-ALL [30] .
To date, RUNX1 has not been linked to RASGRP1 transcriptional regulation, and the role of RUNX1 in autoimmunity remained ambiguous. For example, in patients with active immune thrombocytopenia RUNX1 mRNA expression was elevated [34] , and RUNX1 has been suggested to promote maturation of CD4 + T cells in mice [35] . By contrast, another study showed that RUNX1 deletion in mice led to autoimmune lung disease [36] . Here we provide evidence that decreased expression of RUNX1 leads to reduced RASGRP1 transcription, suggesting a role for RUNX1 in fine-tuning Ras-MAPK signaling in both developing T cells, and peripheral CD4 + T cells.
In conclusion, RasGRP1 expression regulates TCR-induced signaling and thymocyte selection in a dose-dependent manner. Tight regulation of RasGRP1 expression is vital to maintain immunological health and prevent diseases such as leukemia, autoimmunity and immune deficiency ( Fig. 5 ).
Materials and methods

Patients and healthy donors
To investigate the differences in expression levels during disease course, patients with oligoarticular JIA (oJIA) were selected of which at least 30*106 PBMCs from both active disease as well as remission were available (N=8, Table 1 ). In addition, three unpaired samples of oJIA SFMCs were selected. Healthy adult volunteers (n=6) derived PBMCs, collected via the UMCU facility, served as a control group.
Mice C57BL/6 mice wildtype, Rasgrp1 -/-(provided by J. Stone), and Rasgrp1 +/were bred in house at UCSF.
Study approval
This study was conducted according to the principles expressed in the Declaration of Helsinki, and was approved by the UMCU medical ethical committee, study Pharmachild, number 11-499/C. All donors provided written informed consent prior to inclusion in this study for sample collection and analysis, and all donors were numbered to anonymize the samples.
Mice were housed and treated in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) guidelines of the University of California, San Francisco (protocol number AN098375-03B).
HEp-2 ANA Assays
HEp-2 assays were performed utilizing the Nova-Lite kit from INOVA diagnostics. See supplementary methods.
Cells, medium and reagents
PBMCs and SFMCs were extracted using Ficoll-Paque PLUS density gradient centrifugation (GE Healthcare Life Sciences), and stored frozen in FCS+10% DMSO. Jurkat and JPRM441 (low RasGRP1) cells were previously characterized and described [25, 37] . RPMI1640 containing 10 mM HEPES, 2mM L-glutamine, 100 U/ml Penicillin-streptomycin, and 10% FCS was used as culture medium. Starvation was performed in plain RPMI1640 for 30 minutes. When indicated cells were stimulated with PMA (sigma, 20ng/ml), ionomycin (1 uM). min on ice. After washing with FACS buffer, cells were incubated with anti-phospho-ERK, washed, and incubated with secondary antibody. Cells were then washed and run on a BD FACSCanto.
Flow cytometry
Magnetic cell isolation of CD4 + T cells
CD4 + T cells were magnetically purified using CD4 + T cell isolation kit and the autoMACS® Serum was applied to slides, stained with IgG-FITC (Jackson Labs) and DAPI (500ng/ml, LifeTechnologies). Slides were imaged on a Keyence BZ-X710 microscope.
Sera were scored blindly by 3 separate researchers as ANA negative or positive. Each slide contained a no serum negative control or a CD45 Wedge B6-129 F1 positive control serum (a gift from the Hermiston lab, UCSF). 
CRISPR-Cas9 editing
DNA affinity purification and LC-MS analysis
Nuclear extracts from Jurkat T cells were generated as described [39] . Oligonucleotides for the DNA affinity purifications were ordered from IDT with the forward strand containing a 5' biotin moiety.
DNA affinity purifications and on-bead trypsin digestion was performed as described [26] . Tryptic peptides from SNP variant pull-downs were desalted using Stage (stop and go extraction) tips [40] , and then subjected to stable isotope di-methyl labeling [41] on the Stage tips. Matching light and heavy peptides were then combined and samples were finally subjected to LC-MS and subsequent data analyses using MaxQuant [42] and R essentially as described.
shRNA transduction
Lentiviral particles were produced in HEK293T cells using third generation packaging factors.
shRNA plasmids were used from the Mission library (Sigma), for RUNX1 (TRCN0000338427, TRCN0000338490, and TRCN0000338489), and non-targeting shRNA control (SHC002). Jurkat cells were infected by spinoculation in the presence of 8μg/ml of polybrene for 3 hours at 22°C at 800rpm in a table-top centrifuge. Cells were selected with 1μg/ml of puromycin 24 hours after infection.
Western Blot
Cells were lysed in SDS buffer, and lysates were run on SDS-page gel and transferred to a PVDF membrane. After blocking for 1 hour in 3% Bovine Serum Albumin (Roche) in TBS-T, membranes were incubated overnight at 4°C with primary antibodies for RasGRP1 (JR-E80-2 [9] , 1:1500), RUNX1 (ab23980, Abcam, 1:1000), or α-tubulin (T6074, Sigma, 1:2000) in blocking buffer, followed by secondary antibodies in TBS-T for 1 hour at RT. Proteins were visualized using enhanced chemiluminescence. 
Figure legends
